AGP Picks
View all

American Financial Tribune
Provided by AGP

American Financial Tribune: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Financial Tribune.

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

Press releases published on July 24, 2026

$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law
Jul. 24, 2026

$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law

Indeterminate GlobeNewswire
$Z, $ZG Fraud Notification: Zillow Sued for Fraud Over Misrepresentations about its Anticompetitive Agreement – Investors Notified to Contact BFA Law
Jul. 24, 2026

$Z, $ZG Fraud Notification: Zillow Sued for Fraud Over Misrepresentations about its Anticompetitive Agreement – Investors Notified to Contact BFA Law

Indeterminate GlobeNewswire
MannKind Announces $50 Million Private Placement
Jul. 24, 2026

MannKind Announces $50 Million Private Placement

Indeterminate GlobeNewswire
$ADMA Fraud Notification: ADMA Biologics Sued for Fraud Over Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law
Jul. 24, 2026

$ADMA Fraud Notification: ADMA Biologics Sued for Fraud Over Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law

Indeterminate GlobeNewswire
Einride to Host First Half 2026 Earnings Conference Call on August 18, 2026
Jul. 24, 2026

Einride to Host First Half 2026 Earnings Conference Call on August 18, 2026

Indeterminate GlobeNewswire
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
Jul. 24, 2026

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

Indeterminate GlobeNewswire
Nova Minerals Highlights Strategic Alignment with U.S. Defense Supply Chain Priorities Under White House Executive Order
Jul. 24, 2026

Nova Minerals Highlights Strategic Alignment with U.S. Defense Supply Chain Priorities Under White House Executive Order

Indeterminate GlobeNewswire
Ragnarok Origin Classic Officially Launched in North, Central and South America on July 23, 2026
Jul. 24, 2026

Ragnarok Origin Classic Officially Launched in North, Central and South America on July 23, 2026

Indeterminate GlobeNewswire
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Jul. 24, 2026

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Indeterminate GlobeNewswire
Wetour Robotics Outlines Orchestra Platform for Wearable Robotics Powered by NVIDIA Jetson
Jul. 24, 2026

Wetour Robotics Outlines Orchestra Platform for Wearable Robotics Powered by NVIDIA Jetson

Indeterminate GlobeNewswire
ALPHEA Secures $5M Strategic Funding
Jul. 24, 2026

ALPHEA Secures $5M Strategic Funding

Indeterminate GlobeNewswire
Codexis Announces Pricing of Public Offering of Common Stock
Jul. 24, 2026

Codexis Announces Pricing of Public Offering of Common Stock

Indeterminate GlobeNewswire
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Jul. 24, 2026

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

American Financial Tribune

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.